Clinical trials: CINV
Vomiting
Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)
This study is being conducted to demonstrate that aprepitant (MK-0869) prevents nausea and vomiting caused by emetogenic cancer chemotherapy in adolescent participants.
- Trial name
- NCT00080444
- Testing
- aprepitant, ondansetron, dexamethasone
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
To Analyze and Compare the Efficacy and Safety of Ondansetron and Tablet for the Prevention of Moderate and Hypoemetic Chemotherapy
Comparative Study on the Efficacy and Safety of Ondansetron Oral Membrane for the Prevention of Vomiting During Moderate Hypoemetic Chemotherapy
Children aged 4-15 years scheduled to receive Moderate or low emetic chemotherapy were randomly assigned to arm-A (Ondansetron mouth soluble film) or arm-B (Ondansetron tablet).
- Trial name
- Ondansetron (NCT06371014)
- Testing
- Ondansetron oral membrane
- Volunteers
- 200 people
- Sponsor
- Shanghai Children's Medical Center
Nausea, Vomiting
Laser Acupuncture Against Nausea in Children
To investigate whether nonthermal low level laser acupuncture has beneficial effects on nausea and vomiting in children receiving highly emetogenic chemotherapy for a malignant solid tumor.
- Conditions
- Nausea, Vomiting, Cancer
- Trial name
- NCT00528554
- Testing
- laser acupuncture
- Where
- 2 sites in Germany
- Volunteers
- 25 people
- Sponsor
- University Children Hospital Homburg
Neoplasms, Child
VR to Improve CINV, Sleep and Pain Among Children With Cancer in HK
Chemotherapy-induced nausea and vomiting, sleep quality and pain are the common symptoms experienced by children with cancer. These symptoms significantly devastate the children's quality of life.
- Conditions
- Neoplasms, Child, Nausea, Vomiting
- Trial name
- NCT04853303
- Testing
- Hypnosis VR
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- The Hong Kong Polytechnic University
Chemotherapy-Induced Nausea and Vomiting (CINV)
Effect of Mandala Coloring on Nausea, Fatigue, and Well-Being in Chemotherapy Patients
This study aims to evaluate the effect of mandala coloring on nausea, vomiting, fatigue, and psychological well-being in cancer patients receiving chemotherapy.
- Trial name
- MANDALACHEMO (NCT07581119)
- Testing
- Mandala Coloring Intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 85 people
- Sponsor
- University of Gaziantep
Chemotherapy Induced Nausea and Vomiting
Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years
The purpose of this study is to determine the dosing strategy for adolescents aged 6 to 12 years.
- Trial name
- NCT01596413
- Testing
- Sancuso, IV granisetron
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Chemotherapy Induced Nausea and Vomiting
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years
The purpose of this study is to determine the dosing strategy for adolescents aged 2 to 5 years.
- Trial name
- NCT01596426
- Testing
- Sancuso, IV granisetron
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Neoplasms
Clinical on the Safety and Efficacy of Fosaprepitant Dimeglumine for Injection in the Prevention of CINV.
To evaluate the safety of Fosaprepitant Dimeglumine Injection for the prevention of nausea and vomiting caused by tumor chemotherapy drugs, analyze the characteristics of the applicable population and clinical medication of…
- Trial name
- COSEFDIP (NCT05755659)
- Testing
- Fosaprepitant Dimeglumine for Injection
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Xijing Hospital
Chemotherapy-induced Nausea and Vomiting
Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)
The purpose of this study was to determine the appropriate dosing regimen of fosaprepitant, when administered with ondansetron (with or without dexamethasone), for the prevention of CINV in children from birth to <17 years of…
- Trial name
- NCT01697579
- Testing
- Fosaprepitant, Ondansetron, 5-hydroxytryptamine 3 antagonist
- Volunteers
- 240 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy Induced Nausea and Vomiting
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)
This study will compare the safety and efficacy of a three-day oral aprepitant regimen (aprepitant plus ondansetron) to ondansetron alone in the prevention of chemotherapy-induced nausea and vomiting (CINV) in the 120 hours…
- Trial name
- NCT01362530
- Testing
- Aprepitant 125 mg, Aprepitant 80 mg, Aprepitant powder for suspension (PFS)
- Volunteers
- 307 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-induced Nausea and Vomiting
To Study the Safety and Effectiveness of a Granisetron Patch to Treat Chemotherapy-Induced Nausea and Vomiting (CINV)
To study the safety and effectiveness of a granisetron patch to treat Chemotherapy-Induced Nausea and Vomiting (CINV)
- Trial name
- NCT00273468
- Testing
- Granisetron
- Volunteers
- 630 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Chemotherapy-induced Nausea and Vomiting
Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)
The purpose of this study is to evaluate the efficacy and safety of fosaprepitant (MK-0517) plus ondansetron versus ondansetron alone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric participants…
- Trial name
- NCT02519842
- Testing
- Fosaprepitant, Ondansetron, Dexamethasone
- Volunteers
- 75 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy Induced Nausea and Vomiting
Dolasetron for the Prevention of CINV in Children With Acute Lymphoblastic Leukemia
This is a prospective, multicenter, real-world study of 500 participants with childhood acute lymphoblastic leukemia who are scheduled to receive dolasetron mesylate injection for prophylaxis against chemotherapy-induced nausea…
- Trial name
- NCT06756022
- Testing
- Dolasetron mesylate injection
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Anhui Provincial Children's Hospital
Olanzapine, CINV
Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer
This study aims to investigate the efficacy and safety of olanzapine combined with fosaprepitant, ondansetron and dexamethasone compared with placebo combined with fosaprepitant, ondansetron and dexamethasone in the prevention of…
- Conditions
- Olanzapine, CINV, Testicular Cancer by AJCC V6 and V7 Stage, Cisplatin
- Trial name
- NCT05244577
- Testing
- Olanzapine Tablets
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Shi Yanxia
Pediatric Cancer, Chemotherapy-induced Nausea and Vomiting
Efficacy of Ear Acupuncture in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients
Chemotherapy is a cancer therapy performed on advanced cancer with quite good success, but this therapy has quite a lot of side effects.
- Conditions
- Pediatric Cancer, Chemotherapy-induced Nausea and Vomiting, Chemotherapy Effect
- Trial name
- NCT05851625
- Testing
- Press needle acupuncture, Plesterin
- Where
- Indonesia
- Volunteers
- 64 people
- Sponsor
- Universitas Indonesia
Chemotherapy-induced Nausea and Vomiting
Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)
The purpose of this study is to evaluate the safety and tolerability of a 3-day intravenous (IV) fosaprepitant dimeglumine (MK-0517) regimen for the prevention of CINV in pediatric participants scheduled to receive emetogenic…
- Trial name
- NCT04054193
- Testing
- Fosaprepitant Dimeglumine, 5-HT3 antagonist, Dexamethasone
- Where
- 26 sites in United States, Greece and 7 more
- Volunteers
- 103 people
- Sponsor
- Merck Sharp & Dohme LLC
Nausea
The BARF Project: A Pilot Study Using the BARF Scale to Assess CINV in Children
In this pilot study, the Baxter Retching Faces (BARF) Scale will be used to assess chemotherapy induced nausea and vomiting (CINV) in the pediatric cancer population during chemotherapy admissions, and the corresponding…
- Trial name
- NCT04678947
- Testing
- Baxter Retching Faces (BARF) scale
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Washington University School of Medicine
Nausea and Vomiting Chemotherapy-Induced, Nausea Post Chemotherapy
Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)
Chemotherapy often causes nausea and vomiting (CINV), and this is a major problem for the children being treated for cancer. To prevent this, a combination of two substances in fixed proportion (IV NEPA) was developed.
- Trial name
- NCT06904235
- Testing
- IV NEPA (fosnetupitant/palonosetron), Reference Treatment: IV ondansetron infusion, Reference Treatment: IV fosaprepitant infusion
- Where
- 20 sites in Greece, Poland and 2 more
- Volunteers
- 95 people
- Sponsor
- Helsinn Healthcare SA
Chemotherapy-induced Nausea and Vomiting (CINV)
PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting
This study is Phase 2 pharmacokinetic (PK) and pharmacodynamic (PD) dose-finding study of oral netupitant administered concomitantly with oral palonosetron in pediatric cancer patients for the prevention of nausea and vomiting…
- Trial name
- CINV (NCT03204279)
- Testing
- Netupitant, Palonosetron
- Where
- 17 sites in United States, Russia and 2 more
- Volunteers
- 67 people
- Sponsor
- Helsinn Healthcare SA
Chemotherapy-Induced Nausea and Vomiting
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
The primary objective is to evaluate the efficacy of two different doses of IV palonosetron in the prevention of chemotherapy induced nausea and vomiting in MEC and HEC patients through 120 hours after start of chemotherapy in…
- Trial name
- NCT01442376
- Testing
- Palonosetron, Ondansetron
- Where
- 67 sites in United States, Argentina and 14 more
- Volunteers
- 502 people
- Sponsor
- Helsinn Healthcare SA